drugset

drugset / Trial / NCT05583526

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

NCT05583526 ↗

Phase 3 Completed 607 enrolled Pfizer

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Timeline

Start: 2022-12-01
Primary completion: 2026-02-05
Completion: 2026-02-05

Publications

Lukic T, Ghosh P, Napatalung L, Wang C, Kurosky SK, Hamzavi I, Sinclair R, Xiang L, Steil K, Rosmarin D, Parsad D, Ezzedine K, Adiri R. Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. Dermatol Ther (Heidelb). 2026 Jul;16(7):3709-3727. doi: 10.1007/s13555-026-01724-y. Epub 2026 May 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ritlecitinib	Small molecule	50 mg	Oral

Indications